NAS:RADX (Australia)
Â
ADR
$
3.66
-0.74 (-17.25%)
10:08 PM EST
Business Description
Radiopharm Theranostics Ltd
ISIN : US75041J1016
Share Class Description:
RADX: ADRTotal Employee Number:
14Description
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.52 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -2.81 | |||||
Beneish M-Score | 56.29 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 41.5 | |||||
3-Year EPS without NRI Growth Rate | 52.5 | |||||
3-Year FCF Growth Rate | 54.7 | |||||
3-Year Book Growth Rate | -56.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 33.22 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 10.5 | |||||
9-Day RSI | 21.46 | |||||
14-Day RSI | 29.29 | |||||
3-1 Month Momentum % | -8.2 | |||||
6-1 Month Momentum % | -16.02 | |||||
12-1 Month Momentum % | -13.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.67 | |||||
Quick Ratio | 2.67 | |||||
Cash Ratio | 1.95 | |||||
Days Sales Outstanding | 454.32 | |||||
Days Payable | 539 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -103.7 | |||||
Shareholder Yield % | -120.13 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 1.07 | |||||
Operating Margin % | -953.51 | |||||
Net Margin % | -1055.38 | |||||
EBITDA Margin % | -1050.56 | |||||
FCF Margin % | -1002.31 | |||||
OCF Margin % | -1002.31 | |||||
ROE % | -91.21 | |||||
ROA % | -45.83 | |||||
ROIC % | -64.14 | |||||
3-Year ROIIC % | 153.02 | |||||
ROC (Joel Greenblatt) % | -66971.93 | |||||
ROCE % | -55.78 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 9.5 | |||||
PB Ratio | 1 | |||||
EV-to-EBIT | -0.36 | |||||
EV-to-EBITDA | -0.36 | |||||
EV-to-Revenue | 3.83 | |||||
EV-to-Forward-Revenue | 5.75 | |||||
EV-to-FCF | -0.38 | |||||
Earnings Yield (Greenblatt) % | -277.78 | |||||
FCF Yield % | -81.55 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RADX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Radiopharm Theranostics Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.341 | ||
| EPS (TTM) ($) | -3.383 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 33.36 | ||
| 14-Day RSI | 29.29 | ||
| 14-Day ATR ($) | 0.300463 | ||
| 20-Day SMA ($) | 4.250805 | ||
| 12-1 Month Momentum % | -13.21 | ||
| 52-Week Range ($) | 2.73 - 16.25 | ||
| Shares Outstanding (Mil) | 7.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Radiopharm Theranostics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Radiopharm Theranostics Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-11-20 11:00 | In 118 days | ||
| Annual report for 2026 | 2026-09-17 | In 53 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-28 | In 33 days | ||
| Guidance call for 2026 | 2026-04-28 | 4.65 (+3.33%) | ||
| Third quarter earnings results for 2026 | 2026-04-22 | 4.66 (-2.00%) | ||
| Second quarter earnings results for 2026 | 2026-01-28 | 4.92 (-1.80%) | ||
| General meeting for 2025 | 2025-11-20 11:00 | 4.62 (+8.96%) | ||
| Depositary Receipts Virtual Investor Conference | 2025-11-04 12:30 | 4.88 (-6.87%) | ||
| Annual report for 2025 | 2025-09-17 | 7.00 (+7.03%) | ||
| Fourth quarter earnings results for 2025 | 2025-08-29 | 5.70 (-1.72%) |
Show
Entries
Radiopharm Theranostics Ltd Frequently Asked Questions
What is Radiopharm Theranostics Ltd(RADX)'s stock price today?
The current price of RADX is $3.66. The 52 week high of RADX is $16.25 and 52 week low is $2.73.
When is next earnings date of Radiopharm Theranostics Ltd(RADX)?
The next earnings date of Radiopharm Theranostics Ltd(RADX) is 2026-08-28 Est..
Does Radiopharm Theranostics Ltd(RADX) pay dividends? If so, how much?
Radiopharm Theranostics Ltd(RADX) does not pay dividend.
Guru Commentaries on NAS:RADX
No articles.
Press Release
Articles on Radiopharm Theranostics Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers